Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Clinical trial NCT02965716 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02965716
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Melanoma Recurrent Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Melanoma

Start date: 2018-06-05
Primary completion: 2023-06-30
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.